Showing 7411-7420 of 8649 results for "".
- Haag-Streit to Focus on Surgical Microscopes in Ophthalmologyhttps://modernod.com/news/haag-streit-to-focus-on-surgical-microscopes-in-ophthalmology/2480524/Haag-Streit announced that it was focus its business moving forward on ophthalmology—discontinuting its surgical product portfolio in neurosurgery, spine surgery, ENT and plastic-reconstructive surgery. "For our customers, this focus on eye care will allow us to offer so
- Mitotech Granted Orphan Drug Designation by FDA for Visomitin in LHONhttps://modernod.com/news/mitotech-granted-orphan-drug-designation-by-fda-for-visomitin-in-lhon/2480520/Luxembourg-based Mitotech SA announced that the FDA has granted orphan drug designation (ODD) for the company’s topical cardiolipin peroxidation inhibitor, Visomitin, for the treatment of Leber’s Hereditary Optic Neuropathy (LHON), a rare inherited condition that can lead to blin
- GenSight Biologics Confirms Sustained Efficacy and Safety of Bilateral Lumevoq Injections at 2-Year Follow-Up of REFLECT Phase 3 Trialhttps://modernod.com/news/gensight-biologics-confirms-sustained-efficacy-and-safety-of-bilateral-lumevoq-injections-at-2-year-follow-up-of-reflect-phase-3-trial/2480513/GenSight Biologics reported topline efficacy and safety results at 2 years post-treatment administration in the REFLECT Phase 3 clinical trial with Lumevoq. The results show sustained efficacy and safety for bilateral intravitreal injection of the gene therapy, including better efficacy compared
- Kiora Reports KIO-101 is Safe and Tolerable for Dry Eye Diseasehttps://modernod.com/news/kiora-reports-kio-101-is-safe-and-tolerable-for-dry-eye-disease/2480512/Kiora Pharmaceuticals announced topline data from its vehicle-controlled, randomized safety study of KIO-101 eyedrops. The study evaluated 24 healthy subjects and 21 patients diagnosed with ocular surface inflammation, a driver of dry eye disease. The results demonstrated favorable safe
- I-MED Pharma USA Gains Exclusive Distribution Rights for ESW Vision’s E>Eye and Tearcheck in the United Stateshttps://modernod.com/news/i-med-pharma-usa-gains-exclusive-distribution-rights-for-esw-visions-eeye-and-tearcheck-in-the-united-states/2480505/I-MED Pharma has announced the expansion of their strategic partnership with ESW Vision in France to be their exclusive distributor in the United States. Through I-MED Pharma USA, two dry eye devices will be available directly to all eye care professionals across the country. E>Eye i
- Study: Warning Signs of Sight Loss Could be Identified Before Vision Deteriorateshttps://modernod.com/news/study-warning-signs-of-sight-loss-could-be-identified-before-vision-deteriorates/2480502/A new study has shown that the signs of age related macular degeneration can set in earlier than previously thought – even before patients begin to lose their sight. The findings open the door for research into earlier treatment that could help slow down the onset of the condition the most
- Omeros to Sell Omidria Franchise to Rayner in a Deal Worth More Than $1 Billionhttps://modernod.com/news/omeros-to-sell-omidria-franchise-to-rayner-in-a-deal-worth-more-than-1-billion/2480488/Omeros announced that it has entered into a definitive agreement for the sale of Omidria to Rayner Surgical Group. The transaction, which is expected to close on or before December 31, 2021, includes an upfront payment of $125 million with an additional $200 million in
- Implandata Wins Medica Innovation World Cup – 1st Place of 300 Digital Health Ventureshttps://modernod.com/news/implandata-wins-medica-innovation-world-cup-1st-place-of-300-digital-health-ventures/2480485/Implandata Ophthalmic Products was awarded 1st place at the
- Nicox’s Positive Post Hoc Results from NCX 4251 Phase 2b Mississippi Trial Suggest Path Forward in Dry Eye Diseasehttps://modernod.com/news/nicoxs-positive-post-hoc-results-from-ncx-4251-phase-2b-mississippi-trial-suggest-path-forward-in-dry-eye-disease/2480480/Nicox SA announced positive post hoc results from its Mississippi Phase 2b clinical trial suggesting that once-daily dosed NCX 4251, fluticasone propionate ophth
- Oyster Point Pharma Expands Executive Leadership Team to Support Commercialization of Tyrvaya Nasal Sprayhttps://modernod.com/news/oyster-point-pharma-announces-expansion-of-executive-leadership-team-to-support-commercialization-of-tyrvaya-nasal-spray/2480475/Oyster Point Pharma announced the promotion of Barry Rosenfeld, JD, as General Counsel; and Raegan A. McClain, JD, LLM, CCEP, as Chief Compliance Officer, both of whom will join the executive leadership team. “We are thrilled to expand our executive